Work

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Year: 2023
Type: other
Abstract: Supplemental Figure S4: Binding of CLDN6-23-ADC (5 μg/ml) in artificial cell lines overexpressing CLDN3, CLDN4, CLDN6 or CLDN9 by flow cytometry.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4378982557
Cites:
Cited by:
Related to: 7